The April 2023 catch-up price reductions are causing significant concern across the biopharmaceutical sector and while the framework has captured many recently reimbursed brands it has the appearance of targeting one particular group of medicines. …
The appearance of a pricing policy targeting one group of medicines
August 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 - - Australian Biotech -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News